Use of Dupilumab and Eosinophil Targeted Therapy in Treating Angiolymphoid Hyperplasia With Eosinophilia

Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign angioproliferative disorder with an uncertain pathogenesis.¹ The treatment of ALHE includes surgical excision, destructive therapies, and medical therapies, many of which are often ineffective.² In this article, we describe the clinical response to medications targeting eosinophilic inflammation in the treatment of ALHE, including the novel use of dupilumab, which was associated with complete resolution.